Trial Profile
A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowering Treatment in Chinese Participants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Atorvastatin/ezetimibe (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 28 Sep 2022 Primary endpoint (Percent Change from Baseline in LDL-C at Week 12 (Cohort B)) has been met, according to Results published in the Clinical Therapeutics.
- 28 Sep 2022 Primary endpoint (Percent Change from Baseline in LDL-C at Week 12 (Cohort A)) has been met, according to Results published in the Clinical Therapeutics.
- 28 Sep 2022 Results comparing efficacy and tolerability of a fixed-dose combination (FDC) of ezetimibe/atorvastatin (EZ/AS) with those of escalating doses of atorvastatin monotherapy in Chinese patients with hypercholesterolemia uncontrolled with statin monotherapy, published in the Clinical Therapeutics.